Potentiation of the gastric antisecretory activity of histamine H2-receptor antagonists by clebopride.
The substituted benzamide, clebopride, at doses (0.03-3 mg kg-1 i.p.) that were without effect per se on the secretion of gastric acid in pylorus ligated (Shay) rats, potentiated the antisecretory effects of the histamine H2 receptor antagonists cimetidine and ranitidine in this model but not those of the muscarine receptor antagonist pirenzepine nor those of the proton pump inhibitor omeprazole. By contrast, clebopride was without influence on the inhibitory effects of cimetidine on pentagastrin-induced secretion in perfused stomach (Ghosh and Schild) preparations in anaesthetized rats. The significance of these findings is discussed in relation to the previously described potentiating effects of clebopride on the anti-ulcer activity of cimetidine in various experimental models, and the potential beneficial effects of such combined therapy in the clinic.
D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D002927:Cimetidine / Q000494:pharmacology*; D004357:Drug Synergism; D005744:Gastric Acid / Q000378:metabolism*; D006635:Histamine H2 Antagonists; D008297:Male; D009853:Omeprazole / Q000494:pharmacology; D010890:Pirenzepine / Q000494:pharmacology; D011708:Pylorus / Q000187:drug effects; D011899:Ranitidine / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D001549:Benzamides; D006635:Histamine H2 Antagonists; D010890:Pirenzepine; D002927:Cimetidine; D011899:Ranitidine; C014417:clebopride; D009853:Omeprazole